MVR-T3011
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for MVR-T3011, covering 2025-10-08 to 2025-10-08. Get the full timeline:
Most recent: Clinical Trial Update: A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors [Phase 1, Phase 2]